What is Roth Capital’s Estimate for Beyond Air Q3 Earnings?

Beyond Air, Inc. (NASDAQ:XAIR) – Research analysts at Roth Capital lifted their Q3 2025 earnings estimates for shares of Beyond Air in a research report issued on Tuesday, November 12th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings of ($0.23) per share for the quarter, up from their previous estimate of ($0.27). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Beyond Air’s current full-year earnings is ($0.92) per share. Roth Capital also issued estimates for Beyond Air’s Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.01) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.53) EPS.

Beyond Air (NASDAQ:XAIR) last announced its quarterly earnings data on Monday, November 11th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.02. Beyond Air had a negative return on equity of 227.29% and a negative net margin of 2,369.17%. The firm had revenue of $0.80 million during the quarter, compared to analyst estimates of $1.19 million. During the same period in the previous year, the company earned ($0.51) earnings per share.

Other equities analysts have also recently issued reports about the company. Piper Sandler reduced their price objective on Beyond Air from $3.50 to $1.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. Roth Mkm restated a “buy” rating and issued a $2.00 price target on shares of Beyond Air in a research report on Friday, August 16th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $3.67.

Beyond Air Price Performance

Shares of XAIR opened at $0.50 on Friday. Beyond Air has a 52 week low of $0.30 and a 52 week high of $2.36. The company has a current ratio of 5.76, a quick ratio of 2.42 and a debt-to-equity ratio of 0.37. The firm has a market cap of $23.67 million, a price-to-earnings ratio of -0.36 and a beta of -0.18. The stock has a 50 day moving average of $0.41 and a 200-day moving average of $0.67.

Institutional Trading of Beyond Air

Several hedge funds have recently bought and sold shares of XAIR. Point72 Asia Singapore Pte. Ltd. bought a new position in Beyond Air in the 2nd quarter worth about $47,000. Soros Fund Management LLC bought a new stake in shares of Beyond Air during the third quarter valued at approximately $573,000. Vanguard Group Inc. boosted its position in shares of Beyond Air by 5.0% during the first quarter. Vanguard Group Inc. now owns 1,399,298 shares of the company’s stock worth $2,435,000 after buying an additional 66,224 shares during the period. Finally, Gendell Jeffrey L grew its holdings in Beyond Air by 30.4% in the 1st quarter. Gendell Jeffrey L now owns 1,461,071 shares of the company’s stock worth $2,542,000 after buying an additional 340,774 shares in the last quarter. 31.50% of the stock is currently owned by institutional investors.

Insider Transactions at Beyond Air

In other news, CEO Steven A. Lisi purchased 1,476,626 shares of Beyond Air stock in a transaction dated Thursday, September 26th. The stock was bought at an average price of $0.50 per share, with a total value of $738,313.00. Following the completion of the acquisition, the chief executive officer now owns 3,249,411 shares in the company, valued at $1,624,705.50. The trade was a 83.29 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 20.10% of the company’s stock.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.